From RCD pathways to precision oncology: A spatially-aware approach in HCC

References

[1] Sung H , Ferlay J , Siegel RL , et al. Global cancer statistics 2020:GLOBOCAN estimates. CA Cancer J Clin. 2021; 71 (3): 209- 249.

[2] Llovet JM , Kelley RK , Villanueva A , et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7: 6.

[3] Yao Y , Wu S , Leiyang Y , Li M . Prediction of prognosis and immunological features in hepatocellular carcinoma based on non-apoptotic regulatory cell death genes. Asia-Pacific J Clin Oncol. 2025; e14204.

[4] Llovet JM , Montal R , Sia D , Finn RS . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15 (10): 599- 616.

[5] Ma R , He Y , Wang J , et al. Spatial transcriptomics reveals immune remodeling in HCC after immunotherapy. Cell Rep Med. 2022; 3 (8): 100630.

[6] Marx V . Method of the year:spatially resolved transcriptomics. Nat Methods. 2021; 18 (1): 9- 14.

[7] Chen R , Liu Q , Song Y , et al. Integrating spatial transcriptomics and AI for precision oncology. Trends Cancer. 2023; 9 (1): 37- 54.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.